Point-of-Care Genetic Tests for Infectious Disease: Legal Considerations

摘要: Personalized medicine will play an important role in the treatment of infectious diseases. Molecular microbiology diagnostics have potential to identify pathogens with great accuracy and rapidity. The speed identification is particularly crucial effective clinical management many infections. An complement precision diagnostic techniques moving towards point-of-care application, avoid costly delays associated transport laboratory analysis. Point-of-care molecular are expected a significant impact combating hospital acquired infections (‘HAIs’). HAIs major cause increased morbidity death among patients health care settings globally. These often antibiotic resistant, affect already weakened patients. It hoped that eventually allow for rapid particular strain pathogen(s), even unculturable polymicrobial This article considers how existing legal normative framework governing hospitals’ responses may introduction rapid, diagnostics. To this end, we carried out review international, national, institutional guidelines addressing duties prevent, control, rapidly diagnose HAIs. We also reviewed relevant legislation case law Canada United States. In particular, consider if complex hospitals helps or hinders adoption implementation tools. conclude health-care institutions likely come under increasing pressure – both ethical adopt as part their response